Fresenius Divests Brazilian Sites To EMS Amid Structural Streamlining

The Company Sold A Generic Injectable Manufacturing Plant For An Undisclosed Sum

The divestment marks a further step in Fresenius’ ongoing strategy towards a more optimized and simplified company structure while doubling down on new endeavors in the Biopharma space.

Brazil's medicines regulator announces maximum price adjustments permitted in 2025. (Shutterstock)

More from Deals

More from Generics Bulletin